Company news

Lipocine Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154

February 5, 2024

Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals

February 1, 2024

Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada

January 17, 2024

Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023

November 12, 2023

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023

November 7, 2023

Lipocine to Present Clinical Data on LPCN 1148 at The Liver Meeting® 2023

October 31, 2023

Lipocine Completes Successful Meeting with FDA on LPCN 1154 in Postpartum Depression

October 25, 2023

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2023

August 9, 2023

LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis

July 26, 2023

Lipocine to Present LPCN 1148 and LPCN 1144 at the EASL Congress 2023

June 6, 2023

Positive Topline Clinical Results Support Streamlined Development Pathway for LPCN 1154, Lipocine's Oral Candidate for Rapid Relief of Depression

May 15, 2023

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2023

May 10, 2023

Lipocine Announces Pro Rata Distribution of Series B Preferred Stock to its Holders of Common Stock

March 9, 2023

Lipocine Announces Financial Results for the Year Ended December 31, 2022

March 9, 2023

Lipocine Completes Enrollment of LPCN 1148 Phase 2 Study for Decompensated Cirrhosis

December 18, 2022

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2022

November 8, 2022

Lipocine Announces Senior Leadership Appointments to Advance its CNS-Focused Pipeline

November 2, 2022

Lipocine Announces Strategic Realignment and Forward Focus on Treating CNS Disorders

September 25, 2022

Lipocine Announces Favorable Regulatory Pathway on Oral LPCN 1154 for Post-Partum Depression (PPD)

September 14, 2022

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2022

August 7, 2022

FDA Clears LPCN 2101 IND for Adult Epilepsy Treatment

July 10, 2022

Lipocine granted US patents directed to CNS and liver programs

June 13, 2022

Lipocine announces presentation at 2022 epilepsy foundation pipeline conference

June 5, 2022

Lipocine Announces Positive LPCN 1144 NASH Open Label Extension Study Results

May 11, 2022

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2022

May 8, 2022

Lipocine announces board of director appointments

April 10, 2022

Lipocine announces its partner received FDA approval of TLANDO™

March 28, 2022

Lipocine Announces Financial Results for the Year Ended December 31, 2021

March 8, 2022

Lipocine Announces Regulatory Guidance on LPCN 1144 in Non-cirrhotic NASH

February 28, 2022

Lipocine announces its partner received FDA acceptance of NDA resubmission for TLANDO®

February 2, 2022

Lipocine Announces Peer-Reviewed Publication of Phase 3 Study Results for TLANDO®

January 26, 2022

Lipocine announces patient dosed in its Phase 2 study with LPCN 1148 for management of liver cirrhosis

December 21, 2021

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2021

November 9, 2021

Lipocine Announces FDA Grants Fast Track Designation to LPCN 1144 for Treatment of Non-Cirrhotic NASH

November 3, 2021

Lipocine Announces Multiple Poster Presentations at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021

October 31, 2021

Lipocine And Antares Pharma Enter Into U.S. Licensing Agreement To Commercialize TLANDO®

October 17, 2021

Lipocine Announces FDA Affirmation Of Class 1 NDA Resubmission For TLANDO®

September 27, 2021

Lipocine's LPCN 1144 Met Non-Alcoholic Steatohepatitis ("NASH") Resolution Regulatory Endpoint in Phase 2 LiFT Study

August 24, 2021

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2021

August 4, 2021

Lipocine Announces Settlement With Clarus Therapeutics

July 13, 2021

Lipocine Announces Presentations at The International Liver Congress™ 2021 Digital Event

June 22, 2021

FDA Clears LPCN 1154 IND Application for a Phase 2 Postpartum Depression Study

June 13, 2021

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2021

May 5, 2021

Lipocine Announces Financial Results For The Year Ended December 31, 2020

March 10, 2021

Lipocine Announces Publication in Journal of Endocrinological Investigation Highlighting the Potential of LPCN 1144 in the Treatment of NASH and Hepatic Fibrosis

March 3, 2021

Lipocine Announces Presentations on TLANDO™ at ENDO 2021 Conference

March 2, 2021

Lipocine Closes Underwritten Public Offering Of Common Stock

January 27, 2021

Lipocine Prices $25 Million Underwritten Public Offering Of Common Stock

January 25, 2021

Lipocine Announces Launch Of Public Offering Of Common Stock

January 24, 2021

Lipocine Announces USPTO Declaration Of Interference Between Lipocine And Clarus Patent Applications

January 13, 2021

← Newer news releases · Older news releases →

Decks

The 5 newest of 153 decks. Every deck is listed under its year.